

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

GILEAD SCIENCES, INC.

Plaintiff,

v.

APOTEX, INC., LUPIN LIMITED, LAURUS  
LABS LIMITED, SHILPA MEDICARE  
LIMITED, SUNSHINE LAKE PHARMA CO.,  
LTD., NATCO PHARMA LIMITED, CIPLA  
LIMITED, MACLEODS PHARMACEUTICALS  
LTD., HETERO USA INC., HETERO LABS  
LIMITED UNIT-V AND HETERO LABS  
LIMITED,

Defendants.

C.A. No. 20-cv-00189-MN

**CONSENT JUDGMENT AND ORDER**

This action for patent infringement having been brought by Plaintiff Gilead Sciences, Inc. (“Gilead”) against defendants Hetero USA Inc., Hetero Labs Limited, and Hetero Labs Limited Unit-V (“Hetero”) for infringement of U.S. Patent Nos. 7,390,791; 8,754,065; and 9,296,769.

Gilead and Hetero (“the Parties”) have agreed to the terms and conditions in a confidential Settlement and License Agreement (the “Agreement”) and accordingly, have agreed to terminate the pending litigation by the entry of this Judgment and Order; and

The Parties now consent to this Judgment and Order.

IT IS HEREBY ORDERED, ADJUDGED AND DECREED:

1. This Court has jurisdiction over the Parties and subject matter of this action.
2. All affirmative defenses, claims and counterclaims, which have been or could have been raised by Gilead against Hetero and its Affiliates, or by Hetero and its Affiliates against Gilead, in this action are hereby dismissed without prejudice. For purposes of this Judgment and

Order, “Affiliates” means any entity controlling, controlled by, or under common control with Hetero, but only as long as such control continues, where “control” and its correlates means (a) the ownership of at least fifty percent (50%) of the equity or beneficial interest of such entity, (b) the right to vote for or appoint a majority of the board of directors or other governing body of such entity, or (c) the power, whether pursuant to contract, ownership of securities, or otherwise, to direct the management and policies of such entity.

3. Except as otherwise provided by the Parties’ Agreement, Hetero and its Affiliates are hereby enjoined from making, having made, using, having used, offering for sale, having offered for sale, selling, or having sold in the United States, or importing or having imported into the United States, the products of ANDA No. 214179 and ANDA No. 211850 (collectively, “Hetero ANDAs”) until permitted under the Parties’ Agreement.

4. The Parties waive all right to appeal from this Judgment and Order.

5. This Court shall retain jurisdiction of this action and over the parties for purposes of enforcement of the provisions of this Judgment and Order.

6. As provided in the Agreement, Parties are permitted to notify FDA in writing of the relevant terms of the Agreement.

7. Each Party is to bear its own costs and attorneys’ fees.

/s/ Grayson P. Sundermeir

Douglas E. McCann (#3852)  
Grayson P. Sundermeir (#6517)  
Fish & Richardson P.C.  
222 Delaware Avenue, 17th Floor  
Wilmington, DE 19801  
(302) 652-5070  
dmccann@fr.com; sundermeir@fr.com


*Attorneys for Plaintiff  
Gilead Sciences, Inc.*

/s/ Adam W. Poff

Adam W. Poff (#3990)  
YOUNG CONAWAY STARGATT  
& TAYLOR, LLP  
Rodney Square  
1000 North King Street  
Wilmington, DE 19801  
(302) 571-6642  
apoff@ycst.com

*Attorney for Defendants  
Hetero Labs Limited, Hetero USA, Inc., and  
Hetero Labs Ltd. Unit V*

**IT IS SO ORDERED** this 12th day of September 2022.

  
The Honorable Maryellen Noreika  
United States District Judge